```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:SSSPTA1647PXH
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Sep 17  IMSworld Pharmaceutical Company Directory name change
                  to PHARMASEARCH
 NEWS  3  Oct 09  Korean abstracts now included in Derwent World Patents
                  Index
 NEWS  4  Oct 09  Number of Derwent World Patents Index updates increased
 NEWS  5  Oct 15  Calculated properties now in the REGISTRY/ZREGISTRY File
 NEWS  6  Oct 22  Over 1 million reactions added to CASREACT
 NEWS  7  Oct 22  DGENE GETSIM has been improved
 NEWS  8  Oct 29  AAASD no longer available
 NEWS  9  Nov 19  New Search Capabilities  USPATFULL and USPAT2
 NEWS 10  Nov 19  TOXCENTER(SM) - new toxicology file now available on STN
 NEWS 11  Nov 29  COPPERLIT now available on STN
 NEWS 12  Nov 29  DWPI revisions to NTIS and US Provisional Numbers
 NEWS 13  Nov 30  Files VETU and VETB to have open access
 NEWS 14  Dec 10  WPINDEX/WPIDS/WPIX New and Revised Manual Codes for 2002
 NEWS 15  Dec 10  DGENE BLAST Homology Search
 NEWS 16  Dec 17  WELDASEARCH now available on STN
 NEWS 17  Dec 17  STANDARDS now available on STN
 NEWS 18  Dec 17  New fields for DPCI
 NEWS 19  Dec 19  CAS Roles modified
 NEWS 20  Dec 19  1907-1946 data and page images added to CA and CAplus
 NEWS 21  Jan 25  BLAST(R) searching in REGISTRY available in STN on the Web
 NEWS 22  Jan 25  Searching with the P indicator for Preparations
 NEWS 23  Jan 29  FSTA has been reloaded and moves to weekly updates
 NEWS 24  Feb 01  DKILIT now produced by FIZ Karlsruhe and has a new update
                  frequency
 NEWS 25  Feb 19  Access via Tymnet and SprintNet Eliminated Effective 3/31/02

 NEWS EXPRESS  February 1 CURRENT WINDOWS VERSION IS V6.0d,
               CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
               AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *


FILE 'HOME' ENTERED AT 14:22:14 ON 01 MAR 2002

=> file biosis caplus medline
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 0.45       0.45
```

FILE 'BIOSIS' ENTERED AT 14:24:01 ON 01 MAR 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CAPLUS' ENTERED AT 14:24:01 ON 01 MAR 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 14:24:01 ON 01 MAR 2002

=>
=> s polymeric (w) prodrug
L1 255 POLYMERIC (W) PRODRUG

=> s Met-Nle
L2 100 MET-NLE

=> s 1 and 2
L3 7589691 1 AND 2

=>

=> s l1 and l2
L4 0 L1 AND L2

=> s Met-beta-Ala
L5 9 MET-BETA-ALA

=> s l1 and l5
L6 0 L1 AND L5

=> s Gln-Gly
L7 1227 GLN-GLY

=> s l1 and l7
L8 0 L1 AND L7

=> s Asp-Pro
L9 1504 ASP-PRO

=> s l1 and l9
L10 0 L1 AND L9

=> s dipeptide linking arm
L11 0 DIPEPTIDE LINKING ARM

=> s dipeptide
L12 37490 DIPEPTIDE

=> s l1 and l12
L13 3 L1 AND L12

=> d ibib abs l13 1-3

L13 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 2001:227708 BIOSIS
DOCUMENT NUMBER: PREV200100227708
TITLE: **Polymeric prodrug** for release of an antitumoral agent by specific enzymes.
AUTHOR(S): Cavallaro, Gennara; Pitarresi, Giovanna; Licciardi, Mariano; Giammona, Gaetano (1)
CORPORATE SOURCE: (1) Dipartimento di Chimica e Tecnologie Farmaceutiche, Via Archirafi 32, 90123, Palermo: gaegiamm@unipa.it Italy
SOURCE: Bioconjugate Chemistry, (March April, 2001) Vol. 12, No. 2, pp. 143-151. print.
ISSN: 1043-1802.
DOCUMENT TYPE: Article
LANGUAGE: English
SUMMARY LANGUAGE: English

AB The clinical usefulness of antitumor chemotherapy has been strongly limited by the lack of specificity of most anticancer drugs, which act also against healthy cells. The aim of this work was to design, synthesize, and evaluate a macromolecular prodrug of Cytarabine, a known antitumor drug, which is a specific substrate for plasmin enzyme whose concentration is high in various kinds of tumor mass as a result of plasminogen activator secretion. alpha,beta-Poly(N-hydroxyethyl)-DL-aspartamide (PHEA), a known synthetic and biocompatible polyamino acid, was used as a drug carrier, and Cytarabine was linked to PHEA by D-Val-Leu-Lys spacer synthesized beginning from Cbz-D-Val-LeuOH **dipeptide** and N6-CbzLys methyl ester. The content of Cytarabine in the purified PHEA-D-Val-Leu-Lys-Cytarabine conjugate was equal to 3% w/w. In vitro experiments in the presence of plasmin evidenced the ability of this enzyme to strongly increase drug release from the macromolecular prodrug, as well as plasma incubation shows high stability of drug-polymer linkage. The direct linkage of Cytarabine to PHEA was also performed and, like PHEA-D-Val-Leu-Lys-Cytarabine conjugate, the obtained PHEA-Cytarabine conjugate showed high stability in plasma, but no release of Cytarabine was revealed in the presence of plasmin.

L13 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:156311 CAPLUS
DOCUMENT NUMBER: 134:344484
TITLE: **Polymeric Prodrug** for Release of an Antitumoral Agent by Specific Enzymes
AUTHOR(S): Cavallaro, Gennara; Pitarresi, Giovanna; Licciardi, Mariano; Giammona, Gaetano
CORPORATE SOURCE: Dipartimento di Chimica e Tecnologie Farmaceutiche, Palermo, 90123, Italy
SOURCE: Bioconjugate Chem. (2001), 12(2), 143-151
CODEN: BCCHES; ISSN: 1043-1802
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The clin. usefulness of antitumor chemotherapy has been strongly limited by the lack of specificity of most anticancer drugs, which act also against healthy cells. The aim of this work was to design, synthesize, and evaluate a macromol. prodrug of cytarabine, a known antitumor drug, which is a specific substrate for plasmin enzyme whose concn. is high in various kinds of tumor mass as a result of plasminogen activator secretion. .alpha.,.beta.-Poly(N-hydroxyethyl)-DL-aspartamide (PHEA), a known synthetic and biocompatible polyamino acid, was used as a drug carrier, and Cytarabine was linked to PHEA by D-Val-Leu-Lys spacer synthesized beginning from Cbz-D-Val-LeuOH **dipeptide** and N6-CbzLys Me ester. The content of Cytarabine in the purified PHEA-D-Val-Leu-Lys-cytarabine conjugate was equal to 3% wt./wt. In vitro expts. in the presence of plasmin evidenced the ability of this enzyme to strongly increase drug release from the macromol. prodrug, as well as plasma incubation shows high stability of drug-polymer linkage. The direct linkage of cytarabine to PHEA was also performed and, like PHEA-D-Val-Leu-Lys-cytarabine conjugate, the obtained PHEA-cytarabine conjugate showed high stability in plasma, but no release of cytarabine was revealed in the presence of plasmin.
REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 3 OF 3 MEDLINE
ACCESSION NUMBER: 2001459729 MEDLINE
DOCUMENT NUMBER: 21213485 PubMed ID: 11312674
TITLE: **Polymeric prodrug** for release of an antitumoral agent by specific enzymes.
AUTHOR: Cavallaro G; Pitarresi G; Licciardi M; Giammona G
CORPORATE SOURCE: Dipartimento di Chimica e Tecnologie Farmaceutiche, Via Archirafi 32, 90123 Palermo, Italia.
SOURCE: BIOCONJUGATE CHEMISTRY, (2001 Mar-Apr) 12 (2) 143-51.
Journal code: A1T; 9010319. ISSN: 1043-1802.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English

FILE SEGMENT: Priorit[redacted]ournals
ENTRY MONTH: 200108
ENTRY DATE: Entered STN: 20010820
Last Updated on STN: 20010820
Entered Medline: 20010816

AB The clinical usefulness of antitumor chemotherapy has been strongly limited by the lack of specificity of most anticancer drugs, which act also against healthy cells. The aim of this work was to design, synthesize, and evaluate a macromolecular prodrug of Cytarabine, a known antitumor drug, which is a specific substrate for plasmin enzyme whose concentration is high in various kinds of tumor mass as a result of plasminogen activator secretion. alpha,beta-Poly(N-hydroxyethyl)-DL-aspartamide (PHEA), a known synthetic and biocompatible polyamino acid, was used as a drug carrier, and Cytarabine was linked to PHEA by D-Val-Leu-Lys spacer synthesized beginning from Cbz-D-Val-LeuOH **dipeptide** and N6-CbzLys methyl ester. The content of Cytarabine in the purified PHEA-D-Val-Leu-Lys-Cytarabine conjugate was equal to 3% w/w. In vitro experiments in the presence of plasmin evidenced the ability of this enzyme to strongly increase drug release from the macromolecular prodrug, as well as plasma incubation shows high stability of drug-polymer linkage. The direct linkage of Cytarabine to PHEA was also performed and, like PHEA-D-Val-Leu-Lys-Cytarabine conjugate, the obtained PHEA-Cytarabine conjugate showed high stability in plasma, but no release of Cytarabine was revealed in the presence of plasmin.

=> d his

(FILE 'HOME' ENTERED AT 14:22:14 ON 01 MAR 2002)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 14:24:01 ON 01 MAR 2002
L1 255 S POLYMERIC (W) PRODRUG
L2 100 S MET-NLE
L3 7589691 S 1 AND 2
L4 0 S L1 AND L2
L5 9 S MET-BETA-ALA
L6 0 S L1 AND L5
L7 1227 S GLN-GLY
L8 0 S L1 AND L7
L9 1504 S ASP-PRO
L10 0 S L1 AND L9
L11 0 S DIPEPTIDE LINKING ARM
L12 37490 S DIPEPTIDE
L13 3 S L1 AND L12

=> s polymeric (w) drug (w) conjugate
L14 17 POLYMERIC (W) DRUG (W) CONJUGATE

=> s dipeptide
L15 37490 DIPEPTIDE

=> s l14 and l15
L16 0 L14 AND L15

=> s drug (w) polymer (w) derivatives
L17 1 DRUG (W) POLYMER (W) DERIVATIVES

=> d l17

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1991:566605 CAPLUS
DN 115:166605
TI Biologically active **drug polymer derivatives**
IN Veronese, Francesco; Sartore, Luciana; Orsolini, Piero; Deghenghi, Romano
PA Debiopharm S. A., Switz.
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9101758	A1	19910221	WO 1990-EP1261	19900726
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2038935	AA	19910208	CA 1990-2038935	19900726
	CA 2038935	C	19981208		
	EP 437563	A1	19910724	EP 1990-910711	19900726
	EP 437563	B1	19950222		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04501121	T2	19920227	JP 1990-510696	19900726
	ES 2069082	T3	19950501	ES 1990-910711	19900726
	US 5286637	A	19940215	US 1993-1434	19930107
PRAI	GB 1989-18009		19890807		
	GB 1989-19618		19890830		
	WO 1990-EP1261		19900726		
	US 1991-681493		19910603		

=> \d ibib abs l17
\D IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d ibib abs l17

L17 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1991:566605 CAPLUS
DOCUMENT NUMBER: 115:166605
TITLE: Biologically active **drug polymer derivatives**
INVENTOR(S): Veronese, Francesco; Sartore, Luciana; Orsolini, Piero; Deghenghi, Romano
PATENT ASSIGNEE(S): Debiopharm S. A., Switz.
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9101758	A1	19910221	WO 1990-EP1261	19900726
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2038935	AA	19910208	CA 1990-2038935	19900726
CA 2038935	C	19981208		
EP 437563	A1	19910724	EP 1990-910711	19900726
EP 437563	B1	19950222		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 04501121	T2	19920227	JP 1990-510696	19900726
ES 2069082	T3	19950501	ES 1990-910711	19900726
US 5286637	A	19940215	US 1993-1434	19930107

PRIORITY APPLN. INFO.:
GB 1989-18009 19890807
GB 1989-19618 19890830
WO 1990-EP1261 19900726
US 1991-681493 19910603

AB Biol. active protein derivs. useful as medicaments comprise RO(CH2CH2O)n(CO)NHX(CO) (R = lower alkyl; n = 25-250; X when combined with the adjacent NH and CO groups represents amino acid, dipeptide or tripeptide residue; Z when combined with the adjacent NH group represents a peptide, protein, NH- or NH2-contg. drug residue). A method for prepg. the protein derivs. are detailed. Monomethoxypolyethylene glycol glycine succinimidyl ester (prepn. given) was reacted with superoxide dismutase. The product was dried at low temp. under vacuum, dissolved, and concd. The product was stable after 6 such cycles while the unmodified enzyme

lost .gtoreq.15% of it[redacted]ctivity under the same conditi[redacted]

=> d his

(FILE 'HOME' ENTERED AT 14:22:14 ON 01 MAR 2002)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 14:24:01 ON 01 MAR 2002

L1	255	S	POLYMERIC (W) PRODRUG
L2	100	S	MET-NLE
L3	7589691	S	1 AND 2
L4	0	S	L1 AND L2
L5	9	S	MET-BETA-ALA
L6	0	S	L1 AND L5
L7	1227	S	GLN-GLY
L8	0	S	L1 AND L7
L9	1504	S	ASP-PRO
L10	0	S	L1 AND L9
L11	0	S	DIPEPTIDE LINKING ARM
L12	37490	S	DIPEPTIDE
L13	3	S	L1 AND L12
L14	17	S	POLYMERIC (W) DRUG (W) CONJUGATE
L15	37490	S	DIPEPTIDE
L16	0	S	L14 AND L15
L17	1	S	DRUG (W) POLYMER (W) DERIVATIVES